Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.57 |
| ▸ | GSK3A | P49840 | 4/20 | 0.57 |
| ▸ | SRC | P12931 | 3/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.53 |
| ▸ | CDK2 | P24941 | 2/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ACP1 | P24666 | 3/20 | 0.52 |
| ▸ | PDE5A | O76074 | 7/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL786219 | 0.95 | GSK3B (0.55) | GSK3BGSK3ASRCAURKAEIF2AK2 | |
| SCHEMBL785989 | 0.93 | PDE5A (0.55) | GSK3BGSK3ASRCAURKAEIF2AK2 | |
| SCHEMBL786300 | 0.89 | GSK3B (0.48) | GSK3BGSK3ASRCAURKAEIF2AK2 | |
| SCHEMBL786649 | 0.89 | LATS1 (0.54) | GSK3BGSK3ASRCAURKACCNA2 | |
| SCHEMBL786689 | 0.89 | LMNA (0.50) | GSK3BGSK3ASRCAURKAEIF2AK2 | |
| SCHEMBL2207310 | 0.85 | APP (0.46) | GSK3BGSK3ASRCCCNA2CDK2 | |
| SCHEMBL27595377 | 0.85 | PDE5A (0.58) | ABCG2MEN1KMT2APDE5A | |
| SCHEMBL2202604 | 0.84 | PAK4 (0.43) | GSK3BGSK3ASRCAURKAEIF2AK2 | |
| SCHEMBL785576 | 0.84 | GSK3A (0.64) | GSK3BGSK3ASRCAURKAEIF2AK2 | |
| SCHEMBL786157 | 0.83 | CYP1A2 (0.59) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124392-B2 | Crystal structure of Aurora-2 protein and binding pockets thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-28 | — | — | US | claimed |
| EP-1549318-B1 | CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF | VERTEX PHARMA (US) | 2010-02-17 | — | — | EP | claimed |
| US-7361492-B2 | for computer aided drug design and drug screening for inhibitors of this cancer-related serine/threonine kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-22 | — | — | US | claimed |
| EP-1549318-A4 | CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF | VERTEX PHARMA (US) | 2006-03-08 | — | — | EP | claimed |
| EP-1549318-A2 | CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2005-07-06 | — | — | EP | claimed |
| US-20050143402-A1 | Crystal structure of aurora-2 protein and binding pockets thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-30 | — | — | US | claimed |
| WO-2003092607-A2 | CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-11-13 | — | — | WO | claimed |
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-8524720-B2 | Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524720-B2 | Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524720-B2 | Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-6613776-B2 | Protein serine/threonine kinase inhibitors used for treating diseases such as cancer, diabetes and Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-02 | — | — | US | disclosed |
| US-6610677-B2 | Enhancing glycogen synthesis, lowering blood levels of glucose, treating colon, ovarian, or breast cancer, treating diabetes, treating schizophrenia | VERTEX PHARMACEUTICALS INCORPORATED | 2003-08-26 | — | — | US | disclosed |
| US-20030083327-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-01 | — | — | US | disclosed |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-24 | — | — | US | disclosed |
| US-20030073687-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-17 | — | — | US | disclosed |
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-03 | — | — | US | disclosed |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3A | GSK3B 4/4885GSK3A 3/4885SRC 305/4885 |
| US-20030083327-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | GSK3B 3/4885GSK3A 4/4885SRC 256/4885 |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | GSK3B 3/4885GSK3A 4/4885SRC 294/4885 |
| US-20030073687-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | GSK3B 3/4885GSK3A 4/4885SRC 427/4885 |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885SRC 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.